Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|9|3|226-233

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.9, Iss.3, 2012-03, pp. : 226-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New therapies for castrate-resistant prostate cancer

By Williams Stephen B   Lay Aaron H   Lau Clayton S   Josephson David Y   Wilson Timothy G   Choueiri Toni K   Pal Sumanta K  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2069-2074

Informa Healthcare

Access to resources Recommend Favorite

Castrate-resistant prostate cancer: therapeutic strategies

By Harzstark Andrea L   Small Eric J  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 6, 2010-04 ,pp. : 937-945

Informa Healthcare

Access to resources Recommend Favorite

Zibotentan for the treatment of castrate-resistant prostate cancer

By Shepard Dale R   Dreicer Robert  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 899-908

Informa Healthcare

Access to resources Recommend Favorite

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

By Schelman William   Liu Glenn   Wilding George   Morris Thomas   Phung De   Dreicer Robert  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 118-125

Springer Publishing Company

Access to resources Recommend Favorite

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

By Wissing Michel D   van Diest Paul J   van der Wall Elsken   Gelderblom Hans  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 5, 2013-06 ,pp. : 635-661

Informa Healthcare

Access to resources Recommend Favorite